Suppr超能文献

依托孕烯植入剂迁移至血管、胸壁及身体其他远处部位:来自药物警戒数据库的病例

Etonogestrel implant migration to the vasculature, chest wall, and distant body sites: cases from a pharmacovigilance database.

作者信息

Kang Sarah, Niak Ali, Gada Neha, Brinker Allen, Jones S Christopher

机构信息

Division of Pharmacovigilance II, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, USA.

Division of Pharmacovigilance II, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, USA.

出版信息

Contraception. 2017 Dec;96(6):439-445. doi: 10.1016/j.contraception.2017.08.009. Epub 2017 Sep 1.

Abstract

OBJECTIVE

To describe clinical outcomes of etonogestrel implant patients with migration to the vasculature, chest wall and other distant body sites spontaneously reported to the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.

STUDY DESIGN

We performed a standardized Medical Dictionary for Regulatory Activities (MedDRA) query in the FAERS database (through November 15, 2015), with reports coded with one or more MedDRA preferred terms that indicate complications with device placement or migration of the device from the original site of insertion to the vasculature, chest wall and other distant body sites. We excluded any cases previously described in the medical literature.

RESULTS

We identified 38 cases of pronounced etonogestrel implant migration. Migration locations included the lung/pulmonary artery (n=9), chest wall (n=1), vasculature at locations other than the lung/pulmonary artery (n=14) and extravascular migrations (n=14) to other body sites (e.g., the axilla and clavicle/neck line/shoulder). The majority of cases were asymptomatic and detected when the patient desired implant removal; however, seven cases reported symptoms such as pain, discomfort and dyspnea in association with implant migration. Three cases also describe pulmonary fibrosis and skin reactions as a result of implant migration to the vasculature, chest wall and other distant body sites. Sixteen cases reported surgical removal in an operating room setting.

CONCLUSIONS

Our FAERS case series demonstrates etonogestrel implant migration to the vasculature, chest wall and other body sites distant from the site of original insertion.

IMPLICATIONS STATEMENT

As noted by the sponsor in current prescribing information, a key determinant in the risk for etonogestrel contraceptive implant migration appears to be improper insertion technique. Although migration of etonogestrel implants to the vasculature is rare, awareness of migration and education on proper insertion technique may reduce the risk.

摘要

目的

描述向美国食品药品监督管理局不良事件报告系统(FAERS)数据库自发报告的,依托孕烯植入剂迁移至脉管系统、胸壁及其他远处身体部位的患者的临床结局。

研究设计

我们在FAERS数据库(截至2015年11月15日)中进行了标准化的《监管活动医学词典》(MedDRA)查询,报告编码使用一个或多个MedDRA首选术语,这些术语表明了装置植入的并发症或装置从原始植入部位迁移至脉管系统、胸壁及其他远处身体部位。我们排除了医学文献中先前描述过的任何病例。

结果

我们识别出38例依托孕烯植入剂明显迁移的病例。迁移部位包括肺/肺动脉(n = 9)、胸壁(n = 1)、肺/肺动脉以外部位的脉管系统(n = 14)以及向其他身体部位(如腋窝和锁骨/颈部/肩部)的血管外迁移(n = 14)。大多数病例无症状,在患者希望取出植入剂时被发现;然而,7例报告了与植入剂迁移相关的疼痛、不适和呼吸困难等症状。3例还描述了植入剂迁移至脉管系统、胸壁及其他远处身体部位导致的肺纤维化和皮肤反应。16例报告在手术室环境下进行了手术取出。

结论

我们的FAERS病例系列证明了依托孕烯植入剂可迁移至脉管系统、胸壁及远离原始植入部位的其他身体部位。

启示声明

正如申办方在当前的处方信息中所指出的,依托孕烯避孕植入剂迁移风险的一个关键决定因素似乎是不当的插入技术。尽管依托孕烯植入剂迁移至脉管系统的情况罕见,但对迁移的认识和正确插入技术的教育可能会降低风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验